Source of Support: None, Conflict of Interest: None
Ketotifen, an orally active prophylactic agent was given to 30 asthmatic patients of mild to moderate severity. After eight weeks of therapy, 66.3% of patients showed an overall improvement in their respiratory symptoms and ventilatoty functions. Extrinsic asthma had better response (77.7%) as compared to intrinsic group (41.7%). Day time sedation was observed as the most common adverse effect of this drug.